MIM
ZVRA icon

MetLife Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

MetLife Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$245K Sell
26,275
-1,592
-6% -$14.3K ﹤0.01% 2131
2025
Q4 		$250K Buy
27,867
+2,653
+11% +$25.1K ﹤0.01% 2169
2025
Q3 		$240K Sell
25,214
-7,468
-23% -$74.9K ﹤0.01% 2214
2025
Q2 		$288K Hold
32,682
– – ﹤0.01% 1981
2025
Q1 		$245K Sell
32,682
-120
-0.4% -$954 ﹤0.01% 2095
2024
Q4 		$274K Buy
32,802
+9,936
+43% +$84.8K ﹤0.01% 2132
2024
Q3 		$159K Buy
22,866
+1,717
+8% +$11.7K ﹤0.01% 2408
2024
Q2 		$104K Buy
21,149
+9,357
+79% +$44.3K ﹤0.01% 2587
2024
Q1 		$68.4K Sell
11,792
-6,672
-36% -$41K ﹤0.01% 2671
2023
Q4 		$121K Hold
18,464
– – ﹤0.01% 2511
2023
Q3 		$89K Hold
18,464
– – ﹤0.01% 2633
2023
Q2 		$94.2K Buy
+18,464
New +$99.5K ﹤0.01% 2714
2021
Q4 		– Sell
-2,415
Closed -$22.5K – 2557
2021
Q3 		$22.5K Sell
2,415
-9,185
-79% -$92.6K ﹤0.01% 2558
2021
Q2 		$149K Buy
+11,600
New +$125K ﹤0.01% 2329

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

MetLife Investment Management's ZVRA Position: Q1 2026 in Review

MetLife Investment Management reduced its Zevra Therapeutics (ZVRA) stake by 5.7% in Q1 2026, selling an estimated $14.3K and leaving 26,275 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #2131.

MetLife Investment Management first reported a position in ZVRA in Q2 2021 and has held it in 14 quarters since. The position peaked at $288K in Q2 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • MetLife Investment Management held 26,275 shares of Zevra Therapeutics worth $245K as of Q1 2026.
  • MetLife Investment Management sold 1,592 Zevra Therapeutics shares in Q1 2026, an estimated $14.3K.
  • Zevra Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2131 holding.
  • MetLife Investment Management first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • MetLife Investment Management's Zevra Therapeutics position peaked at $288K in Q2 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.